Arbutus Biopharma Income Statement (2010-2025) | ABUS

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)	2.11M	2.33M	3.34M	3.21M	12.58M	14.24M	5.95M	6.25M	6.69M	4.65M	4.66M	2.15M	1.53M	1.73M	1.34M	1.57M	1.76M	10.74M	0.53M	1.05M
Operating items
Depreciation & Amortization - Total (Quarter)	0.44M	0.44M	0.45M
Research & Development (Quarter)	13.78M	15.80M	16.71M	19.21M	18.46M	22.94M	20.05M	22.95M	18.27M	17.69M	20.17M	17.56M	15.40M	15.55M	14.27M	8.81M	8.96M	5.50M	5.78M	5.01M
Selling, General & Administrative (Quarter)	3.88M	4.48M	4.18M	4.60M	4.89M	5.20M	3.49M	4.25M	5.55M	5.98M	5.84M	5.10M	5.31M	7.55M	4.54M	4.71M	5.83M	3.33M	3.04M	3.69M
Restructuring Costs (Quarter)															3.62M	0.10M	12.40M	12.40M	0.10M	0.30M
Other Operating Expenses (Quarter)	-0.31M	0.26M	0.41M	0.19M	0.20M	0.21M	0.21M	1.61M	0.27M	-0.64M	0.20M	0.23M	0.18M	0.21M	0.34M	1.89M	0.27M	-11.97M	0.27M	-2.66M
Operating Expenses (Quarter)	17.79M	20.97M	21.75M	24.00M	23.55M	28.35M	23.76M	28.81M	24.10M	23.04M	26.22M	22.89M	20.89M	23.31M	22.78M	15.51M	27.46M	9.25M	9.19M	6.34M
Operating Income (Quarter)	-15.68M	-18.64M	-18.41M	-20.80M	-10.97M	-14.11M	-17.81M	-22.56M	-17.41M	-18.39M	-21.56M	-20.75M	-19.36M	-21.58M	-21.44M	-13.93M	-25.70M	1.49M	-8.66M	-5.29M
EBIT (Quarter)	-15.68M	-18.64M	-18.41M	-20.80M	-10.97M	-14.11M	-17.81M	-22.56M	-17.41M	-18.39M	-21.56M	-20.75M	-19.36M	-21.58M	-21.44M	-13.93M	-25.70M	1.49M	-8.66M	-5.29M
Non-operating items
Non Operating Investment Income (Quarter)
Interest & Investment Income (Quarter)	0.04M	0.03M	0.03M	0.03M	0.16M	0.40M	0.69M	0.94M	1.27M	1.46M	1.49M	1.47M	1.54M	1.83M	1.75M	1.46M	1.20M	1.04M	0.95M	0.88M
Other Non Operating Income (Quarter)	0.03M	-0.01M	-0.01M	0.01M		0.00M	-0.02M	-0.00M	0.00M	0.00M	0.01M	0.01M	-0.01M	-0.01M	0.01M	-0.03M	0.00M	0.02M	-0.01M	0.00M
Non Operating Income (Quarter)	-0.70M	-0.74M	-0.75M	-0.53M	-0.35M	-0.08M	0.24M	0.63M	1.07M	1.29M	1.45M	1.44M	1.49M	1.79M	1.72M	1.40M	1.17M	1.03M	0.92M	1.53M
Net income details
EBT (Quarter)	-16.38M	-19.39M	-19.16M	-21.32M	-11.32M	-14.19M	-17.57M	-21.93M	-16.34M	-17.09M	-20.10M	-19.31M	-17.86M	-19.79M	-19.72M	-12.50M	-24.53M	2.50M	-7.73M	-4.43M
Tax Provisions (Quarter)					4.44M
Profit After Tax (Quarter)	-16.38M	-19.39M	-19.16M	-21.32M	-15.77M	-14.19M	-17.57M	-21.93M	-16.34M	-17.09M	-20.10M	-19.31M	-17.88M	-19.80M	-19.72M	-12.53M	-24.53M	2.52M	-7.74M	-3.76M
Equity Income (Quarter)
Income from Continuing Operations (Quarter)	-16.38M	-19.39M	-19.16M	-21.32M	-15.77M	-14.19M	-17.57M	-21.93M	-16.34M	-17.09M	-20.10M	-19.31M	-17.86M	-19.79M	-19.72M	-12.50M	-24.53M	2.50M	-7.73M	-4.43M
Consolidated Net Income (Quarter)	-16.38M	-19.39M	-19.16M	-21.32M	-15.77M	-14.19M	-17.57M	-21.93M	-16.34M	-17.09M	-20.10M	-19.31M	-17.86M	-19.79M	-19.72M	-12.50M	-24.53M	2.50M	-7.73M	-4.43M
Income towards Parent Company (Quarter)	-16.38M	-19.39M	-19.16M	-21.32M	-15.77M	-14.19M	-17.57M	-21.93M	-16.34M	-17.09M	-20.10M	-19.31M	-17.86M	-19.79M	-19.72M	-12.50M	-24.53M	2.50M	-7.73M	-4.43M
Preferred Dividend Payments (Quarter)	3.21M	3.27M	5.09M	0.57M
Net Income towards Common Stockholders (Quarter)	-19.59M	-22.65M	-24.25M	-21.89M	-15.77M	-14.19M	-17.57M	-21.93M	-16.34M	-17.09M	-20.10M	-19.31M	-17.86M	-19.79M	-19.72M	-12.50M	-24.53M	2.50M	-7.73M	-4.43M
Additional items
EPS (Basic) (Quarter)	-0.21	-0.23	-0.24	-0.15	-0.11	-0.10	-0.12	-0.14	-0.10	-0.10	-0.12	-0.12	-0.10	-0.11	-0.10	-0.07	-0.13	0.01	-0.04	-0.01
EPS (Weighted Average and Diluted) (Quarter)	-0.21	-0.23	-0.24	-0.15	-0.11	-0.10	-0.12	-0.14	-0.10	-0.10	-0.12	-0.12	-0.10	-0.11	-0.10	-0.07	-0.13	0.01	-0.04	-0.01
Shares Outstanding (Weighted Average) (Quarter)	93.43M	95.15M	101.29M	106.24M	148.43M	148.75M	151.00M	150.94M	161.64M	166.06M	167.51M	165.96M	175.63M	188.04M	184.24M	185.61M	190.71M	191.55M	191.78M	191.60M
Shares Outstanding (Diluted Average) (Quarter)	93.43M	95.15M	97.17M	106.24M	148.43M	148.59M	151.00M	150.94M	161.64M	166.06M	167.51M	165.96M	175.63M	188.04M	184.24M	185.61M	190.71M	192.40M	191.35M	191.60M
EBITDA (Quarter)	-16.38M	-19.42M	-19.19M	-21.47M	-16.84M	-14.88M	-18.47M	-21.42M	-15.48M	-16.93M	-19.52M	-18.85M	-17.82M	-19.73M	-19.50M	-12.58M	-24.56M	2.50M	-7.68M	-3.73M
Interest Expenses (Quarter)	0.77M	0.76M	0.76M	0.56M	0.51M	0.48M	0.43M	0.31M	0.20M	0.17M	0.05M	0.04M	0.04M	0.03M	0.03M	0.03M	0.03M	0.03M	0.02M	0.02M
Shares Outstanding (Quarter)	96.25M	97.70M	1.16M	144.99M	148.73M	148.79M	152.71M	157.46M	165.13M	166.92M	167.70M	169.87M	180.19M	188.74M	189.44M	189.96M	191.48M	191.64M	191.95M	192.53M
Tax Rate (Quarter)					-39.25

Research Tools

Arbutus Biopharma Income Statement (2010-2025) | ABUS

Create an account

Sign In

Reset Password